Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

55.86 -0.04 (-0.07%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

85 86 Next >

3 Blue-Chip Stocks to Buy at 52-Week Lows in May ↗

May 27, 2024

These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one.

Via InvestorPlace

S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25 ↗

May 25, 2024

Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%.

Via Talk Markets

Topics Stocks

Retail Earnings & Consumer Spending: A Closer Look ↗

May 25, 2024

The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies...

Via Talk Markets

Topics Economy Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

(BMY) - Analyzing Bristol-Myers Squibb's Short Interest ↗

May 23, 2024

Via Benzinga

May 23, 2024

This top pharma stock has fallen too far.

Via The Motley Fool

Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity ↗

May 21, 2024

Via Benzinga

Is Bristol Myers' Dividend in Danger? ↗

May 11, 2024

Should investors brace for a dividend cut?

Via The Motley Fool

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗

May 24, 2024

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...

Via Benzinga

Bonds Break Down And Send Everyone To Cash ↗

May 23, 2024

This situation is where the danger, the opportunity, and the action are right now.

Via Talk Markets

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

May 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

May 23, 2024

From Bristol Myers Squibb

Via Business Wire

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗

May 22, 2024

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...

Via Benzinga

Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries

May 22, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign

May 21, 2024

From Bristol Myers Squibb

Via Business Wire

1 Stock I Wouldn't Touch With a 10-Foot Pole ↗

May 21, 2024

This stock isn't as safe as it seems, and now isn't the time to dabble.

Via The Motley Fool

3 Bargain Stocks to Buy Now: May 2024 ↗

May 21, 2024

These bargain stocks to buy provide substantial upside since they are trading at a significant discount to their historical multiples.

Via InvestorPlace

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

May 21, 2024

From Bristol Myers Squibb

Via Business Wire

Large Cap Biopharmaceuticals Performance ↗

May 20, 2024

The biotech sector remains a laggard YTD as can be seen by the IBB.

Via Talk Markets

Insider Trading is Good News for These Stocks

May 20, 2024

Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.

Via MarketBeat

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst ↗

May 17, 2024

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,...

Via Benzinga

Walmart Earnings And The State Of The Consumer ↗

May 16, 2024

This earnings season showed a notable acceleration in the earnings growth pace, which produces a reassuring earnings backdrop for the market.

Via Talk Markets

FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma ↗

May 16, 2024

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high...

Via Benzinga

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

May 16, 2024

From Bristol Myers Squibb

Via Business Wire

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗

May 16, 2024

AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.

Via InvestorPlace

Topics Artificial Intelligence

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

May 15, 2024

From Bristol Myers Squibb

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 14, 2024

Via Benzinga

Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders ↗

May 14, 2024

Using these capture-the-dividend stock strategy for tactical traders can be profitable with high-yield blue-chips.

Via InvestorPlace

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗

May 13, 2024

The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.

Via Investor's Business Daily

Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip ↗

May 12, 2024

Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction.

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today